51st week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100322899 | METHODS OF IMPROVING CENTRAL NERVOUS SYSTEM FUNCTIONING - Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells. | 2010-12-23 |
20100322900 | Treatment of multiple sclerosis with laquinimod - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 2010-12-23 |
20100322901 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF - The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 2010-12-23 |
20100322902 | DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLE, PROCESS FOR PRODUCING THE SAME AND PREPARATION CONTAINING THE MICROPARTICLE - Sustained release microparticles suitable for various types of drugs, or drug-containing sustained release microparticles capable of sustained release of drugs over a period of three days or more and capable of inhibiting initial burst release; a process for producing the same; and preparations containing the microparticles are disclosed. The drug-containing sustained release microparticles comprise a drug other than human growth hormone and a porous apatite derivative, and optionally include a water-soluble bivalent metal compound. The drug-containing sustained release microparticles can be produced by dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; optionally adding an aqueous solution containing a water-soluble bivalent metal compound that may infiltrate into the porous apatite derivative; further adding additives such as a stabilizer to the mixture; and effecting lyophilization or vacuum drying. | 2010-12-23 |
20100322903 | ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to the treatment and prevention of bacteria and bacterial infections. In particular, the present invention relates to engineered bacteriophages used in combination with antimicrobial agents to potentiate the antimicrobial effect and bacterial killing by the antimicrobial agent. The present invention generally relates to methods and compositions comprising engineered bacteriophages and antimicrobial agents for the treatment of bacteria, and more particularly to bacteriophages comprising agents that inhibit antibiotic resistance genes and/or cell survival genes, and/or bacteriophages comprising repressors of SOS response genes or inhibitors of antimicrobial defense genes and/or expressing an agent which increases the sensitivity of bacteria to an antimicrobial agent in combination with at least one antimicrobial agent, and their use thereof. | 2010-12-23 |
20100322904 | COMPOSITION COMPRISING BIFIDOBACTERIUM INFANTIS AND FRUCTO- AND GALACTO-OLIGOSACCHARIDES FOR THE PREVENTION OF INTESTINAL DISCOMFORT IN INFANTS - Compositions comprising bifidobacteria and galactooligosaccharides and fructooligosaccharides are provided that support the introduction of solid weaning foods in the diet of infants that receive infant milk formula or breast milk. | 2010-12-23 |
20100322905 | Compositions and methods for treating pancreatic cancer - The present invention provides a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells. The invention is based on the finding that cyclin D1 shRNA molecules are capable of attenuating tumor growth and interfering with tumor angiogenesis. | 2010-12-23 |
20100322906 | Method for Obtaining Pancreatic Endocrine Cells From Adipose Tissue-Origin Cells - A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on. | 2010-12-23 |
20100322907 | Expansion of Hematopoietic Stem Cells - Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro and in vivo. Also described are methods, compositions and kits related to making an expanded population of hematopoietic stem cells (HSCs) and methods, compositions and kits related to using the expanded population of HSCs. | 2010-12-23 |
20100322908 | COMPOSITIONS AND METHODS FOR AUGMENTATION AND REGENERATION OF LIVING TISSUE IN A SUBJECT - The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive. | 2010-12-23 |
20100322909 | TH1-ASSOCIATED MICRORNAS AND THEIR USE FOR TUMOR IMMUNOTHERAPY - Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL. | 2010-12-23 |
20100322910 | METHODS OF OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided. | 2010-12-23 |
20100322911 | USE OF MICROWAVE IRRADIATION FOR DELIVERY OF MACROMOLECULES - The present invention is directed to methods of delivering macromolecules to a target cell or tissue by microwave irradiation. A target cell or tissue is exposed to one or more macromolecules to be delivered into the desired cell or tissue and irradiated with microwave radiation. The strength or power of the microwave radiation is such that the macromolecules are delivered into the target cell or tissue. Preferably, the strength of the microwave radiation does not significantly impact cell viability in a negative manner (e.g., apoptosis). | 2010-12-23 |
20100322912 | Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Celiac Sprue Patients - Combination enzyme products and methods of use thereof are provided. Aspergillopepsin I is combined with a protease enzyme that provides for an additive or synergistic effect in the digestion of toxic gluten oligopeptides. The enzyme products are useful in the treatment of Celiac Sprue patients, particularly for patients who continue to exhibit signs or symptoms of active disease despite following a gluten-free diet. | 2010-12-23 |
20100322913 | CHIMERIC POLYPEPTIDE COMPRISING THE FRAGMENT B OF SHIGA TOXIN AND PEPTIDES OF THERAPEUTIC INTEREST - The invention pertains to methods for using chimeric polypeptides of the formula: | 2010-12-23 |
20100322914 | PRODRUG ANTI-CANCER THERAPY - Compositions and methods for inhibiting the growth of cancer cells are provided. The cancer cells, the growth of which is inhibited, have constitutively active Abl tyrosine kinase activity due to a t(9;22)(q34;q11) translocation which results in expression of a chimeric Bcr-Abl protein which has constitutively active Abl tyrosine kinase activity that is believed to play an important role in leukemogenesis. The compositions include a modified protein kinase C(PKC) which has an Abl tyrosine kinase target motif. The methods involve administering the modified PCK to an individual to inhibit the growth of cancer cells that have Abl tyrosine kinase activity. | 2010-12-23 |
20100322915 | Protease Variants for Pharmaceutical Use - The invention relates to novel variants of a protease derived from | 2010-12-23 |
20100322916 | DNA REPAIR POLYPEPTIDES AND METHODS OF DELIVERY AND USE - Described herein are pyrimidine dimer-specific glycosylase (PDG) polypeptides and methods of use for repair of damaged DNA. The PDG polypeptides comprise amino acid sequence from T4-PDG, CV-PDG or engineered mutants thereof. The PDG polypeptides further comprise a targeting sequence, such as a nuclear targeting sequence or a mitochondrial targeting sequence, and a protein transduction domain. The mutant PDG polypeptides described herein retain at least some catalytic activity while exhibiting reduced cytotoxicity in wild-type cells. | 2010-12-23 |
20100322917 | PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION - The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by | 2010-12-23 |
20100322918 | Diffusion enhancing compounds and their use alone or with thrombolytics - The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke. | 2010-12-23 |
20100322919 | Antibodies Against a Cancer-Associated Epitope of Variant NFKBIB and Uses Thereof - The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof. | 2010-12-23 |
20100322920 | Human monoclonal antibodies against CD30 - Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2010-12-23 |
20100322921 | METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF - The present invention also discloses the novel use of factor Va inhibitors in the treatment of various disorders caused by the formation of blood clots. | 2010-12-23 |
20100322922 | Neutralization of CD95 Activity Blocks Invasion of glioblastoma Cells In Vivo - The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue. | 2010-12-23 |
20100322923 | Medical Uses of Glucans - The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in an animal comprising administering to said animal an effective amount of a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto. | 2010-12-23 |
20100322924 | Humanized Fc gamma RIIB-Specific Antibodies And Methods Of Use Thereof - The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB. | 2010-12-23 |
20100322925 | ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 2010-12-23 |
20100322926 | METHODS OF USING CADHERIN 11 (CDH11) ANTAGONISTS - The present invention provides novel methods of inhibiting or preventing epithelial-mesenchymal transition (EMT) or endothelial-mesenchymal transition (EnMT), such as EMT or EnMT, associated with fibrosis and chronic tissue rejection. The present invention also provides methods for diagnosing or assessing whether a subject has or is at risk of developing a disease associated with CDH11 expression, as well as methods for determining the prognosis of a subject diagnosed with a CDH11-associated condition. The invention employs CDH11 antagonists to downmodulate CDH11 activity, thereby inhibiting EMT or EnMT. | 2010-12-23 |
20100322927 | GLYCOSYLATED ANTIBODIES - The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof. | 2010-12-23 |
20100322928 | METHODS OF DIAGNOSING, MONITORING TREATMENT AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE. | 2010-12-23 |
20100322929 | ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2010-12-23 |
20100322930 | FIBRONECTIN-BASED BINDING MOLECULES AND THEIR USE - The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder. | 2010-12-23 |
20100322931 | ANTI-VEGF ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF. | 2010-12-23 |
20100322932 | METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES - Methods and related immunoglobulin peptides and fragments thereof are disclosed that enhance the cell-mediated immune response of a patient to deposits of amyloid fibrils. These methods exploit the opsonizing effect of antibodies directed toward amyloid material or its component parts. | 2010-12-23 |
20100322933 | INTRAOPERATIVE TRIFUNCTIONAL ANTIBODY APPLICATION FOR PROPHYLAXIS OF INTRAPERITONEAL TUMOR CELL DISSEMINATION - The invention describes the use of trifunctional bispecific and trispecific antibodies for destroying tumor cells which e.g. are disseminated intraperitoneally due to a surgical intervention, wherein the antibody is administered intraoperatively, preferably directly locally into the abdominal cavity. | 2010-12-23 |
20100322934 | Bispecific, Tetravalent Antigen Binding Proteins - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2010-12-23 |
20100322935 | Tri- or Tetraspecific Antibodies - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 2010-12-23 |
20100322936 | LM-1 ANTIBODIES, FUNCTIONAL FRAGMENTS, LM-1 TARGET ANTIGEN, AND METHODS FOR MAKING AND USING SAME - The invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to LM-1 antigen (e.g., NONO/nmt55). Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a LM-1 antibody, an antibody that binds to LM-1 antigen, or a functional fragment thereof, effective to treat metastasis of the neoplasia, tumor or cancer in the subject. | 2010-12-23 |
20100322937 | EGF receptor epitope peptides and uses thereof - The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided. | 2010-12-23 |
20100322938 | NOVEL CLUSTERIN DERIVED PEPTIDE - Clusterin-derived peptides or homologues or derivatives thereof, pharmaceutical compositions including the same, methods of manufacturing the peptides, homologues, derivatives thereof and compositions including the same, and methods of treating conditions including administering the peptides, homologues, derivatives thereof and compositions including the same, are provided. Also provided are nucleotide sequences encoding the peptides, homologues, derivatives thereof and compositions including the same, antibodies directed to epitopes thereof and fusion proteins including the same | 2010-12-23 |
20100322939 | NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS - The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent. | 2010-12-23 |
20100322940 | IN VITRO MODIFICATION OF GLYCOSYLATION PATTERNS OF RECOMBINANT GLYCOPEPTIDES - This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern. | 2010-12-23 |
20100322941 | Human Anti-IP-10 Antibodies Uses Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-IO, CXCL1O), thereby modulating the interaction between IP-IO and its receptor, CXCR3, and/or modulating the biological activities of IP-IO. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2010-12-23 |
20100322942 | THERAPEUTIC AND PROPHYLACTIC METHODS FOR NEUROMUSCULAR DISORDERS - The disclosure provides methods for treating neuromuscular disorders in mammals. The disclosed methods include administering therapeutically effective amounts of a GDF-8 inhibitor and a corticosteroid to a subject susceptible to, or having, a neuromuscular disorder, so as to maintain desirable levels of muscle function. | 2010-12-23 |
20100322943 | THERAPEUTIC AND DIAGNOSTIC AFFINITY PURIFIED SPECIFIC POLYCLONAL ANTIBODIES - Provided herein are compositions that include a mixture of polyclonal antibodies obtained from the plasma of a plurality of individuals, and methods of making and using the same. | 2010-12-23 |
20100322944 | Anti-bacterial antibodies - A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A. | 2010-12-23 |
20100322945 | IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS - The invention provides means and methods for inducing and/or enhancing immunogenic reproducibility and/or immunogenicity of a compound, comprising at least in part restricting the conformation of said compound. The conformation is preferably restricted by the formation of at least one internal bond within said compound. Protein mimics comprising an amino acid sequence bound to a scaffold and/or a carrier, wherein said amino acid sequence comprises at least one internal SS-bridge, are also herewith provided. | 2010-12-23 |
20100322946 | MULTISPECIFIC ANTIBODIES - The invention provides multispecific antibodies and methods of making and using such antibodies. | 2010-12-23 |
20100322947 | PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-BETA - The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-β as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-β induced by exposure to intense light, such as UV etc. | 2010-12-23 |
20100322948 | Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same - The present invention relates to the identification and use of bone morphogenetic protein (BMP)-binding domains of members of the repulsive guidance molecule (RGM) protein family, and polypeptide fragments and fusion proteins derived therefrom. The domains, i.e., peptide fragments and fusion proteins, according to the invention are suitable as agents for the active or passive immunization of individuals, or as diagnostic and therapeutic agents for use for diseases or medical conditions in whose origin or progression a member of the RGM family and a cellular receptor associated with this molecule, such as neogenin and/or BMP in particular, is involved. The invention further relates to monoclonal and polyclonal antibodies directed against the binding domains according to the invention, and against the polypeptides derived therefrom, and to methods for producing the polypeptides, fusion proteins, and antibodies according to the invention. | 2010-12-23 |
20100322949 | METHODS FOR DIAGNOSING AND TREATING ASTROCYTOMAS - The invention relates to the identification of astrocytoma markers, astrocytoma stem cells and markers of such stem cells, and diagnostic, prognostic and therapeutic methods based on an understanding of the markers and cells. | 2010-12-23 |
20100322950 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD. | 2010-12-23 |
20100322951 | Replication-proficient dsRNA capsids and uses thereof - Compositions and methods useful in the production of proteins in vitro and in vivo are provided. In particular, this invention provides bionanoparticles comprised of replication-proficient, double-stranded RNA (dsRNA) capsids which are capable of transfecting, for example, target bacterial, yeast, plant and mammalian cells, and causing expression of genes of interest in said transfected cells. The bionanoparticles comprised of replication-proficient, dsRNA capsids are also capable of expressing genes of interest in vitro. The genes of interest can encode proteins that are useful, for example, as research reagents, therapeutics and vaccines. Also described are methods that enable the construction of bionanoparticles comprised of replication-proficient dsRNA capsids and methods for transfecting cells with said bionanoparticles and expressing said genes of interest in transfected cells and in vitro. | 2010-12-23 |
20100322952 | COMPOSITIONS FOR AND METHODS OF ENHANCING THE IMMUNE RESPONSE TO ANTIGENS - Compositions comprising the compound of formula are provided herein. Also provided are methods of enhancing an immune response of a subject to an antigen by administering the antigen and the composition. The enhanced immune response may be an humoral immune response, a CD4+T cell response, a CD8+T cell response or result in activation of antigen presenting cells. Methods of enhancing the immune response by intramuscular administration of an antigen and the composition including the compound of formula I are also provided. | 2010-12-23 |
20100322953 | Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions - Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods. | 2010-12-23 |
20100322954 | ENHANCED HIV-1 VACCINES AND METHODS FOR THEIR USE - The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine. | 2010-12-23 |
20100322955 | VIRULENCE GENES, PROTEINS, AND THEIR USE - A series of genes from | 2010-12-23 |
20100322956 | METHODS AND SUBSTANCES FOR THE TREATMENT OF ALZHEIMER'S - The present invention relates to a combination of one or more nucleic acids encoding, (a) in a first open reading frame (i) a promoter, (U) an amyloid peptide, (iii) a cell surface targeting signal, (iv) a transmembrane anchoring domain and (b) in a second open reading frame (i) a group specific antigen (gag). Also the invention relates to a pharmaceutical composition and a vaccine comprising Aβ-retrop articles. | 2010-12-23 |
20100322957 | SECRETION-RELATED BACTERIAL PROTEINS FOR NLRC4 STIMULATION - Introduction of immunomodulatory T3SS polypeptides (IT3SSP's) into cells stimulates a response mediated by NLRC4 intracellularly. Introduction of said IT3SSP into the cells of a subject evoke an innate immune response in the subject. | 2010-12-23 |
20100322958 | MODIFIED SACCHARIDES - Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R | 2010-12-23 |
20100322959 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Methods of using and processes to make an immunogenic composition are also described. | 2010-12-23 |
20100322960 | Ganoderma tsugae Active Substance Having Endothelial Cell-protecting and Atherosclerosis-preventing Effects, Process for Preparing the Same and Composition Containing the Same | 2010-12-23 |
20100322961 | Intranasal Drug Delivery System - The present invention provides an intranasal drug delivery system containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin in the form of oleoresin capsicum used as a carrier to quickly and effectively deliver a drug. | 2010-12-23 |
20100322962 | ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN-NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE - A substituted Norovirus capsid protein monomer, having only the P-domain and called an antigen-Norovirus P-domain monomer, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral form, called an antigen-Norovirus P-particle, that is composed of 24 copies of the antigen-P-domain monomer. Each substituted P-domain monomer will contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus, for example Rotavirus, and can serve as a carrier for presentation of foreign antigens for development of novel vaccines against many infectious and non-infectious diseases. The substituted Norovirus P-particles can be readily produced in | 2010-12-23 |
20100322963 | LOW DOSE INOCULATION WITH TAP FOR ANTI-TUMOR IMMUNITY - A safe and efficacious method of inducing protective immunity in animals against TAP-1 deficient metastatic melanoma is disclosed. The method involves treating the animals with relatively small amounts of a recombinant non-replicating adenovirus encoding human TAP-1 to promote and maintain long term anti-tumor survival, and enhanced memory T-cell subpopulations, even when the treatment effects only a small fraction of metastatic tumor cells. | 2010-12-23 |
20100322964 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 2010-12-23 |
20100322965 | VIRAL VACCINE VECTORS - The present invention relates to a hybrid-viral vector system, in particular, but not exclusively, to a hybrid-viral vector system that can be used as a vaccine vector. | 2010-12-23 |
20100322966 | Method for allogeneic cell therapy - A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens. | 2010-12-23 |
20100322967 | B CELL TOLERANCE INDUCTION - The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor. | 2010-12-23 |
20100322968 | THERAPEUTIC AGENT FOR CANCER - The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses. | 2010-12-23 |
20100322969 | INFLUENZA B VIRUSES HAVING ALTERATIONS IN THE HEMAGLUTININ POLYPEPTIDE - The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection. | 2010-12-23 |
20100322970 | MODIFIED INFLUENZA VIRUS - The present invention provides an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene, more specifically at any one of nucleotide positions 265 to 294 of the M gene as well as an influenza B virus comprising said modified M gene. Further, its use for the preparation of a vaccine and methods for preparing said modified influenza virus are disclosed. | 2010-12-23 |
20100322971 | METHOD FOR PRODUCING VACCINAL VIRAL STRAIN OF A VIRUS OF THE REOVIRIDAE FAMILY - The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus. | 2010-12-23 |
20100322972 | HCV Vaccines For Chronic HCV Patients - The use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections are disclosed. | 2010-12-23 |
20100322973 | ANTI-ALLERGIC AGENT - Provided is an antiallergic agent including, as an active ingredient, a fermentation product of a propionic acid bacterium. | 2010-12-23 |
20100322974 | Targeting the histone code as a bacterial strategy for selectively modulating gene expression - The ospF gene of | 2010-12-23 |
20100322975 | Anti-bacterial Vaccine Compositions - Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines. | 2010-12-23 |
20100322976 | TONIC AND FOOD SUPPLEMENT COMPRISING ALOE VERA AND HONEY - A mixture of honey (preferably manuka honey) with aloe vera extract is concentrated for distribution and then diluted before use as a tonic or food supplement for mammals, particular those with compromised or poorly performing immune systems. In particular (though without limit) the composition is useful in the control of chronic mastitis in dairy cows. | 2010-12-23 |
20100322977 | BIOMATERIALS, COMPOSITIONS, AND METHODS - Embodiments exploit the ability of the organism | 2010-12-23 |
20100322978 | MEDICAL COMPOSITION - It is an object of the present invention to produce a medical composition using a multilayered biopolymer structure. The present invention provides a medical composition of multilayered biopolymer structure of at least two layers, wherein the multilayered biopolymer structure comprises different types of biopolymer structures, and at least one layer of the multilayered biopolymer structure comprises a chemical substance. | 2010-12-23 |
20100322979 | Peptidomimetic Resorbable Peptide-Polymer Hybrid Polyester Nanoparticles - In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes a degradable synthetic polymer chain, a sequence of non-polar amino acids, and a sequence of ionic amino acids. The nanoparticle has a diameter of from about 50 nm to about 150 nm. | 2010-12-23 |
20100322980 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 - The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis. | 2010-12-23 |
20100322981 | BRIGHT INTERFERENCE PIGMENTS - The present invention relates to (interference) pigments comprising a plate-like substrate, a layer of SnO | 2010-12-23 |
20100322982 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2010-12-23 |
20100322983 | Personal-Care Composition - A personal-care composition in the form of an oil-in-water emulsion is disclosed that provides improved skin feel and effective wrinkle-filling. The personal-care composition comprises a silicone elastomer; a silicone fluid; a combination of particulate materials; a polymeric thickener; and water. The combination comprises at least three particulate materials which pack together in order to fill wrinkles. | 2010-12-23 |
20100322984 | ORAL CARE COMPOSITION FOR COMBATING DENTINE HYPERSENSITIVITY - The present invention describes oral care compositions comprising certain surface-coated inorganic oxides and their use for treating dentine hypersensitivity. | 2010-12-23 |
20100322985 | EFFERVESCENT COMPOSITIONS - The present invention is directed to effervescent compositions comprising a basic amino acid. | 2010-12-23 |
20100322986 | COMPOSITIONS AND DEVICES - The present invention provides oral instruments comprising a basic amino acid, to compositions for making such instruments, and to methods of making and using such instruments. | 2010-12-23 |
20100322987 | DENTAL WIPE - The present invention is directed to a dental wipe comprising a basic amino acid or salt thereof. | 2010-12-23 |
20100322988 | COMPOSITIONS AND DEVICES - The present invention provides tooth-whitening compositions comprising a bleaching agent and a baste amino acid, together with devices for application thereof, and methods of use therefor. | 2010-12-23 |
20100322989 | HYDROPHILIC SKIN CLEANING CLOTH - A preferably single-ply, simply and inexpensively manufacturable hydrophilic skin care tissue for disposable use comprising a textile surface ( | 2010-12-23 |
20100322990 | METHODS FOR CONTROLLING PESTS - Ready-to-use foamable pesticide compositions that contain a particulate pesticide suspended therein and applicators for dispensing such compositions. Methods for treating pests such as arthropods by contacting pests with such compositions are also provided. | 2010-12-23 |
20100322991 | HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers. | 2010-12-23 |
20100322992 | Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device - Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque | 2010-12-23 |
20100322993 | INJECTABLE BIOCOMPATIBLE COMPOSITION - The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal. | 2010-12-23 |
20100322994 | PARTICULATE CARTILAGE SYSTEM - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 2010-12-23 |
20100322995 | FISH FOOD CAPSULE - The invention relates to a fish food capsule, comprising a capsule casing and a liquid or suspension-like fish food product enclosed in the capsule casing, wherein a gas phase determining the buoyancy of the fish food capsule is provided in the fish food capsule, and to the use thereof, a fish food kit, and a method for producing the fish food capsule. | 2010-12-23 |
20100322996 | Fluid Absorbent Adhesive Articles - A fluid absorbing pressure sensitive adhesive composition and adhesive articles including the fluid absorbing adhesive that have particular utility in the medical field, and in particular, for use with wound dressings is provided. The adhesive composition has superior fluid handling capacity, moisture vapor transmission and skin adhesion. | 2010-12-23 |
20100322997 | METHOD FOR PRODUCING BIOLOGICALLY INGESTIBLE MICROPARTICLES, BIOLOGICALLY INGESTIBLE MICROPARTICLES, AND DISPERSION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A method of separating biologically ingestible microparticles is used to obtain biologically ingestible microparticles in a thin film fluid formed between two processing surfaces provided with a solution containing a first solvent in which an objective substance to be pulverized is dissolved and a solvent capable of serving as a second solvent in which the solubility of the microparticles is lower than in the first solvent, the two processing surfaces being arranged so as to be able to approach to and separate from each other, at least one of which rotates relative to the other. | 2010-12-23 |
20100322998 | SKIN ULCER PREVENTIVE CURATIVE AGENT CONTAINING HUMAN RECOMBINANT HGF - A neovascularization promoting composition, a granulation formation-promoting composition and a preventive or curative composition for skin ulcer, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain thereof. The provided compositions of the present invention are useful as a drug capable of promoting granulation formation and neovascularization and being effective in tissue restoration, especially as a preventive and curative agent for skin ulcer. | 2010-12-23 |